Non-HIV lentiviral vectors

Alan Kingsman is the Chief Executive of Oxford BioMedica pie. He obtained h is degrees from University of Birmingham, UK, and went on to become a Lectu rer and Professor at the University of Oxford, UK. In 1993 he became Go-Dir ector of the Retrovirus Molecular Biology Group within the Biochemistry Dep artment of Oxford University and was Associate Director of Research at Brit ish Biotech between 1987 and 1990. In 1995 Professor Kingsman co-founded Ox ford BioMedica to develop and commercialise gene technologies arising out o f research undertaken by the Group at the University. The company uses adva nced gene delivery technologies for the treatment of disease in the areas o f oncology, viral infection, neurobiology and genetic deficiency. In Decemb er 1996 Oxford BioMedica was floated on the UK Alternative Investment Marke t of the London Stock Exchange. Professor Kingsman has published more than 130 papers and reviews and is an internationally recognised authority on ge ne expression and retrovirus research.